Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management: (Academic Highlights)
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Article Abstract Click to enlarge page Patients with major depressive disorder (MDD) who have responded to or remitted from antidepressant treatment frequently have persistent residual symptoms (eg, fatigue, sleep problems, cognitive symptoms) that interfere with their functioning and quality of life and significantly increase the risk of relapse. Clinicians need to systematically evaluate for all depressive symptoms at baseline, so that some are not missed and the individual patient's symptoms can be tracked across all phases of treatment. Developing a list of target problems that the patient would like to see improve is a helpful tool in this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationThe Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987
Multiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Conradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“The neurochemical rationale for adjunctive treatments for MDD generally involves (1) increasing the effects of 1 or more neurotransmitters (eg, 5-HT, NE, DA, γ-aminobutyric acid, glutamate) and/or (2) modulating the activity of receptors that may affect specific symptomatic and side effect domains, either directly or…”
BackgroundPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
Cited by
Segal, Z. V., Dimidjian, S., Beck, A., Boggs, J. M., Vanderkruik, R., Metcalf, C. A., Gallop, R., Felder, J. N., & Levy, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4693 · Cited by 159
Oxytocin and stress-related disorders: neurobiological mechanisms and treatment opportunities
Sippel, L. M., Allington, C. E., Pietrzak, R. H., Harpaz-Rotem, I., Mayes, L. C., & Olff, M. (2017) · Chronic Stress · doi:10.1177/2470547016687996 · Cited by 99
“While evidence-based psychotherapies and antidepressant treatments for stress-related disorders have meaningful effects, some of which may actually be mediated by effects on OT,(124) treatments could be improved regarding reduction of side effects, facilitation of more rapid response, and the percentage of individuals…”
BackgroundDimidjian, S., Beck, A., Felder, J. N., Boggs, J. M., Gallop, R., & Segal, Z. V. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.09.004 · Cited by 87
“Relapse risk increases by 16% with each additional episode, and RDS following acute phase treatment are both common and associated with negative prognosis (Zajecka et al., 2013).”
BackgroundKinser, P. A., Elswick, R. K., & Kornstein, S. (2014) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2014.08.014 · Cited by 76
Self-citationSegal, Z. V., Anderson, A. K., Gulamani, T., Dinh Williams, L.-A., Desormeau, P., Ferguson, A., Walsh, K., & Farb, N. A. S. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000351 · Cited by 63
Metadata
- Authors
- Zajecka, J., Kornstein, S. G., & Blier, P.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-04-15
- Volume
- 74
- Issue
- 04
- Pages
- 407-414
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2006555929
- Cited by
- 61
- References
- 15
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management: (Academic Highlights). https://app.cochat.ai/papers/10.4088/jcp.12059ah1
- The paper
- Zajecka, J., Kornstein, S. G., & Blier, P. (2013). Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management: (Academic Highlights). The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.12059ah1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.